Arcturus Therapeutics Endorses Plan Amendment and Re-elects Board
Company Announcements

Arcturus Therapeutics Endorses Plan Amendment and Re-elects Board

Arcturus Therapeutics (ARCT) has shared an update.

Arcturus Therapeutics Holdings Inc. stockholders convened for their annual meeting, endorsing a significant amendment to the company’s equity incentive plan by increasing share allocation to participants by 2 million, totaling 10.75 million shares. Additionally, the assembly re-elected eight board members, validated executive compensation in a non-binding vote, and ratified the appointment of Deloitte & Touche LLP as their independent auditor for the upcoming fiscal year.

For an in-depth examination of ARCT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskArcturus Therapeutics Reports Q3 2024 Financial Results and Milestones
TheFlyArcturus Therapeutics reports Q3 EPS (26c), consensus ($1.22)
Austin AngeloArcturus Therapeutics (ARCT) Q3 Earnings Cheat Sheet
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App